Dermatology · Montgomery, AL
NPI
1326195124
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4712 Berry Blvd
Montgomery, AL, 36106
Phone (334) 834-3094
Groups this clinician bills Medicare through
Medicare paid, 2024
$114K
2,638 services
Medicare patients, 2024
565
Average age 73
Drug cost, 2024
$2.1M
2,781 prescriptions
Company payments, 2025
$52K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Porcia B Love was code 99213 (office e&m - established), 443 times for 296 patients. In total Porcia B Love billed 2,638 services in 36 codes, and Medicare paid $114K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-01-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 443 | 296 | $56.59 | $25K |
| 17003 Destruction Skin Lesion | Office | 416 | 100 | $4.62 | $1,921 |
| 99214 Office E&M - Established | Office | 303 | 223 | $78.46 | $24K |
| 17110 Destruction Skin Lesion | Office | 230 | 178 | $67.91 | $16K |
| 11102 Skin Biopsy | Office | 204 | 182 | $55.54 | $11K |
| 17000 Destruction Skin Lesion | Office | 181 | 139 | $32.32 | $5,850 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 125 | 30 | $0.77 | $95.78 |
| 11900 Skin | Office | 92 | 32 | $37.17 | $3,419 |
| 99204 Office E&M - New | Office | 85 | 85 | $98.41 | $8,365 |
| 11103 Skin Biopsy | Office | 54 | 40 | $35.12 | $1,897 |
| 99203 Office E&M - New | Office | 51 | 51 | $70.13 | $3,576 |
| 99212 Office E&M - Established | Office | 20 | 19 | $35.34 | $707 |
| 11104 Skin Biopsy | Office | 12 | 12 | $73.96 | $888 |
| 17111 Destruction Skin Lesion | Office | 12 | 11 | $88.99 | $1,068 |
By year: 2022 $140K for 3,012 services; 2023 $127K for 2,840 services; 2024 $114K for 2,638 services.
Medicare prescription drug claims, 2024
In 2024, the drug Porcia B Love prescribed most often to Medicare patients was Ketoconazole, with 439 prescriptions and refills. In total Porcia B Love wrote 2,781 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 439 | 454 | 215 | $6,987 |
| Triamcinolone Acetonide Generic | 293 | 310 | 197 | $5,682 |
| Finasteride Generic | 185 | 304 | 58 | $949 |
| Doxycycline Hyclate Generic | 167 | 169 | 109 | $4,418 |
| Fluocinolone Acetonide Fluocinolone/Shower Cap | 129 | 138 | 71 | $6,892 |
| Dupixent Pen Dupilumab | 125 | 128 | 25 | $477K |
| Tretinoin Generic | 125 | 134 | 69 | $11K |
| Clobetasol Propionate Generic | 103 | 105 | 63 | $6,632 |
| Betamethasone Dipropionate Generic | 99 | 101 | 58 | $4,955 |
| Tacrolimus Generic | 83 | 91 | 36 | $13K |
| Fluocinonide Generic | 82 | 84 | 43 | $3,874 |
| Clindamycin Phosphate Generic | 73 | 73 | 27 | $3,386 |
| Mupirocin Generic | 72 | 73 | 47 | $824 |
| Hydrocortisone Generic | 70 | 70 | 41 | $369 |
| Minoxidil Generic | 49 | 95 | 17 | $386 |
Brand drugs: 403 claims; generic drugs: 2,378 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Porcia B Love $52K ($52K in general payments such as food, travel and fees) from 24 companies. The largest payer was Regeneron Healthcare Solutions, Inc. with $20K.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. REGN | 11 | $20K |
| Abbvie Inc. ABBV | 27 | $15K |
| Genzyme Corporation SNY | 12 | $7,829 |
| Lilly USA, LLC LLY | 7 | $6,657 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $350 |
| LEO Pharma Inc. | 8 | $263 |
| Pfizer Inc. PFE | 10 | $245 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 8 | $224 |
| Galderma Laboratories, L.P. GALD.SW | 17 | $208 |
| Kyowa Kirin, Inc. 4151.T | 3 | $185 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.